Domestic sales price and medical insurance reimbursement of decavatinib
Deuterated colexitinib has been approved for marketing in China and has been included in medical insurance according to your information. Common specifications on the market are 6 mg × 7 tablets / boxes. The latest market retail price is about more than 1,000 yuan. This price has obvious advantages over imported versions, making it more accessible to domestic patients.
In overseas markets, the common specifications of the original research version of deuterated colexitinib (such as the US version) are 6 mg × 30 tablets/ box, and its latest selling price is about 50,000 yuan. This price is much higher than the domestic version, mainly due to factors such as import fees, patent protection, logistics and tariffs.

In countries such as Laos and Bangladesh, there are officially marketed generic versions of deuterated colexitinib, and their active ingredients are basically the same as the original drug. Its specifications are 6 mg × 30 tablets / box, the latest market price is about four to five hundred yuan. This price provides a more economical option for patients with limited budgets, but they should ensure that the medicine is from a legitimate source.
Although deuterated colexitinib has been approved in China and is said to be included in medical insurance, the specific reimbursement ratio, deductible line, cap line or provincial and municipal differences have not been disclosed in detailed unified standards. It is recommended that patients consult their local medical insurance designated hospitals or pharmacies before use: including whether the drug is actually covered by medical insurance in their region, how much the patient needs to pay out of pocket, and the reimbursement process. In addition, patients should choose purchasing channels based on their own condition, financial ability, and doctor’s recommendations. Purchasing drugs through formal channels and understanding specific reimbursement policies will help you use the drug more safely and economically.
Reference materials:https://www.drugs.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)